CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Empowering

people living with

rare immunologic diseases 

We develop innovative immunomodulating therapies with the potential to transform the lives of people affected by rare immunologic conditions.

Media

Our latest announcements

Read all press releases

Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)

Regulatory press release

25/06/2025
Hansa Biopharma has carried out a directed cash share issue of approx. mSEK 232 and entered into binding agreement to restructure debt held by NovaQuest, including set-off issue of USD 14.9 million

Regulatory press release

19/06/2025
Hansa Biopharma intends to carry out directed share issue of approximately 10 million shares and has entered into non-binding terms with NovaQuest to restructure debt

Regulatory press release

18/06/2025
Hansa Biopharma to attend BIO International Convention

11/06/2025
Our science

Our unique antibody-cleaving enzyme technology

Our proprietary antibody-cleaving enzymes imilfidase and HNSA-5487 target and inactivate IgG antibodies in the blood and tissues, inhibiting the IgG-mediated immune responses, helping halt the progression of IgG-driven acute autoimmune diseases, as well as enable lifesaving and life altering procedures and therapies.

Our focus area

We aim to address unmet need in conditions where the IgG-driven immune response becomes harmful, or it interferes with the delivery of lifesaving and life altering therapies.

Autoimmune diseases Gene therapy enablement Transplantation enablement

PATIENT STORY

Cris Ann’s Story: fighting for a chance to live

Soon after being told she had kidney disease, Cris Ann learned she is one of the 10-15% of kidney transplant patients in the U.S. who are highly sensitized, making it virtually impossible to find a compatible donor kidney. This is her story.

Read the story

For Investors

Calendar

Upcoming events

17
Jul

Half-year Report for January-June 2025

23
Oct

Interim Report for January-September 2025

View all events
Latest Financial Results

Interim report January-March 2025

Press release Report Presentation Webcast Transcript
View all results

Annual Report 2024
Sustainability Report 2024

Science-led
Patient first
Values driven

Read the reports

Media articles

Discover more

Read all posts

Collaboration across the continuum of care to improve equity for highly sensitized people in kidney transplantation
17/07/2024
A concerted collaboration to advance treatment options for people living with rare diseases
26/06/2024
Fueling the future: the role of biotech in advancing innovative science and delivering new medicines
02/05/2024
Addressing barriers to gene therapy treatment
31/01/2024

Partner with us

Our partnership model is focused in three key areas – drug discovery and development, commercialization and distribution / licensing. 

Partnerships

Join us

Ready for a new career? Check out our job opportunities.

Career opportunities

A truly great place to work

For five years Hansa has been awarded the Great Place To Work designation by the independent institute Great Place To Work®, a global authority on workplace culture, employee experience and leadership behavior. 

Job opportunities

E-mail

Sign up to receive the latest updates

Choose type

I consent to Hansa Biopharma handling my personal data. See our Privacy Policy for information about how we handle personal data.

Thank you. You will get an e-mail message to activate your subscription.